Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 2, 2001 - Issue 11
Submit an article Journal homepage
175
Views
12
CrossRef citations to date
0
Altmetric
Miscellaneous

COX-2 inhibitors compared and contrasted

Ignatius A Tavares Academic Department of Surgery, The Rayne Institute, Guy’s, King’s and St Thomas’ Medical School, King’s College, London, SE5 9NU, UK
&
Alan Bennett Academic Department of Surgery, The Rayne Institute, Guy’s, King’s and St Thomas’ Medical School, King’s College, London, SE5 9NU, UK
Pages 1859-1876 | Published online: 24 Feb 2005

Bibliography

  • VANE JR, WARNER TD: Nomenclaturefor COX-2 inhibitors. Lancet (2000) 356:1373–1374.
  • WARNER TD, GIULIANO F, VOJNOVIC I, BUKASA A, MITCHELL JA, VANE JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Li. USA (1999) 96:7563–7568.
  • ••Important comparison of NSAID COX-1:COX-2 ratios in human whole blood.
  • TAVARES IA, COLLINS PO, BENNETT A: Inhibition of prostanoid synthesis by human gastric mucosa. Aliment. Pharmacol Ther. (1987) 1:617–625.
  • GRETZER B, MARICIC N, RESPONDEK M, SCHULIGOI R, PESKAR BM: Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br j Pharmacol (2001) 132:1565–1573.
  • LICHTENBERGER LM: Where is the that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem. Pharmacol. (2001) 61:631–637.
  • •A reminder that not everyone is convinced about the central role of inhibition of COX-1 and PGs in NSAID-induced gastric mucosal damage.
  • JONES RA: Etodolac: clinical profile of an established selective cyclooxgenase-2 inhibitor. In: Therapeutic Roles of Selective COX-2 Inhibitors. JR Vane, RM Botting (Eds), William Harvey Press, London (2000:482–497.
  • ••A good review of etodolac.
  • BENNETT A, VILLA G: Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Expert Opin. Pharmacother. (2000) 1:277-286. good review of nimesulide.
  • BENNETT A: Nimesulide: a well-established cyclooxygenase-2 inhibitor with other pharmacological properties relevant to inflammatory diseases. In: Therapeutic Roles of Selective COX-2 Inhibitors. Vane JR, Botting RM (Eds), William Harvey Press, London (2001):524–540. good review of nimesulide.
  • DEGNER F, TURCK D, PAIRET M: Meloxicam. Pharmacological, pharmacokinetic and clinical profile. Drugs of Today (1998) 34(Suppl. A):1–22.
  • DEGNER E LANES S, VON RYN J, SIGMUND R: Pharmacological and clinical profile of meloxicam. In: Therapeutic Roles of Selective COX-2 Inhibitors. Vane JR, Botting RM (Eds), William Harvey Press, London (2001):498–523.
  • ••A good review of meloxicam.
  • DAVIES NM, GUDDE TW, LEEUW MAWC: Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis. Expert Opin. Pharmacother. (2001) 2:139–152.
  • ••A good review of celecoxib.
  • LEFKOWITH JB, VERBURG KM, GEISGS: Clinical experience with celecoxib: a 2 specific inhibitor. In: Therapeutic Roles of Selective COX-2 Inhibitors. Vane JR, Botting RIVI (Eds), William Harvey Press, London (2000461–481. good review of celeccedb.
  • HAWKEY CJ: COX-2 inhibitors. Lancet (1999) 307–314.
  • MORRISON B, SIMON TJ, DE TORE L, SPERLING R: Rofecoxib: clinical studies. In: Therapeutic Roles of Selective COX-2 Inhibitors. Vane JR, Botting RIVI (Eds), William Harvey Press, London (2001)541–559.
  • ••A good review of rofecoxib.
  • FERREIRA SH, MONCADA S, VANE JR: Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br Pharmacol (1973) 49:86–97.
  • BROOKS E EMERY JF, EVANS H et al:Interpreting the clinical significance of the differential inhibition of cyclooxygense-1 and cyclooxygenase-2. Rheumatology (1999) 38:779–788.
  • TAKEUCHI K, TANAKA A, SUZUKI K, MIZOGUCHI H: Gastrointestinal sparing anti-inflammatory drugs - effects on ulcerogenic and healing responses. Curr. Pharm. Des. (2001) 7:49–69.
  • WALLACE JL: Selective COX-2 inhibitors:is the water becoming muddy? Trends Pharmacol. ScL (1999) 20:4–6.
  • BONTA IL, PARNHAM MJ: Immunomodulatory-antiinflammatory functions of E-type prostaglandins. Minireview with emphasis on macrophage-mediated effects. IriL j Immuriopharmacol (1982) 4:103–109.
  • •To remind us that not all effects of PGs in inflammation are bad.
  • WILLOUGHBY DA, MOORE AR, COLVILLE-NASH PR, GILROY D: Resolution of inflammation. Int. Immuriopharmacol (2000) 22:1131–1135.
  • RIENDEAU D, PERCIVAL MD, BRIDEAU C et al: Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. j Pharmacol Exp. Ther. (2001) 296:558–566.
  • PAIRET M, VAN RYN J, SCHIEROK H, MAUZ A, TRUMMLITZ G, ENGLEHARDT G: Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4 "-isomer. Inllamm. Res. (1998) 47:270–276.
  • CRYER B, FELDMAN M:-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. j Med. (1998) 104:413–421.
  • RUSSELL R: Endoscopic evaluation of and naproxen, and their relative effects on gastric and duodenal prostaglandins. Rheumatol Int. (1990) 10(Suppl.):17–12.
  • •COX-1-sparing activity of etodolac on human gastric mucosa.
  • LIPSCOMB GR, WALLIS N, ARMSTRONG G, GOODMAN MJ, REES WD: Gastric mucosal adaptation to etodolac and naproxen. Aliment. Pharmacol Ther. (1995) 9:379–385.
  • LAINE L, SLOANE R, FERRETTI M, COMINELLI F: A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Castroiritest. Enclose. (1995) 42:428–433.
  • TAVARES IA: The effects of meloxicam, indomethacin or NS-398 on eicosanoid synthesis by fresh human gastric mucosa. Ailment. Pharmacol Ther (2000) 14:795–799.
  • SHAH AA, THJODLEIFSSON B, MURRAY FE et al: Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Cut (2001) 48:339–346.
  • •COX-1-sparing activity of nimesulide on human gastric mucosa.
  • TAVARES IA, BISHAI PM, BENNETT A: of nimesulide on constitutive and inducible cyclooxygenases. Armeimittelforschung (1995) 45:1093–1095.
  • EHRICH EW, DALLOB A, DE LEPELIERE I et al: Characterization of rofecoxib as a cyclooxygense-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Chi]. Pharmacol Ther (1999) 65:336–347.
  • WRIGHT NJ, GOTTESDIENER K, GARLICK NM et al.: Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology (2001) 120:867–873.
  • •COX-1-sparing activity of rofecoxib on human gastric mucosa.
  • GOLDRING MB, SOHBAT E, ELWELL JM, CHANG JY: Etodolac preserves cartilage-specific phenotype in human chondrocytes: effects on Type II collagen synthesis and associated mRNA levels. Eur. Irillarnm. (1990) 10:10–21.
  • MAUVIEL A, REDINI E LOYAU G, PUJOL JP: Modulation of extracellular matrix metabolism in rabbit articular chondrocytes and human rheumatoid synovial cells by the non-steroidal anti-inflammatory drug etodolac. I: Collagen synthesis. Agents Actions (1990) 31:345–352.
  • BLOT L, MARCELIS A, DEVOGELAER JP, MANICOURT: Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br. I Pharmacol. (2000) 131:1413–1421.
  • BASSLEER C, MAGOTTEAUX J, GEENEN V, MALAISE M: Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes. Pharmacology (1997) 54:49–56.
  • RAINSFORD KD, YING C, SMITH FC: Effects of meloxicam, compared with other NSAIDs, on cartilage proteoglycan metabolism, synovial prostaglandin E2, and production of interleukins 1, 6 and 8, in human and porcine explants in organ culture. j Pharm. Pharmacol (1997) 49:991–998.
  • PELLETIER JP, MARTEL-PELLETIER J: Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage. Drugs (1993) 46\(Supp1.1):34–39.
  • BARRACCHINI A, FRANCESCHINI N, AMICOSANTE G et al: Can non-steroidal anti-inflammatory drugs act as modulators? An in-vitro study of inhibition of collagenase activity. Pharm. Pharmacol (1998) 50:1417–1423.
  • HENROTIN YE, LABASSE AH, SIMONIS PE et al.: Effects of nimesulide and sodium diclofenac on interleukin-6, interleukin-8, proteoglycans and prostaglandin E2 production by human articular chondrocytes in vitro. Chi]. Exp. Rheumatol. (1999) 17:151–160.
  • SHARMA S, RASTOGI S, GUPTA V, ROHTAGI D, GULATI P: Comparative and safety of nimesulide versus piroxicam in osteoarthritis with special reference to chondroprotection. Am. Therap. (1999) 6:191–197.
  • MUKHERJEE P, RACHITA C, AISEN PS, PASINETTI GM: Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. OM Exp. Rheumatol. (2001) 19(1 Suppl. 22):57–S11.
  • CHAN CC, BOYCE S, BRIDEAU C et al.: Rofecoxib Vi0XX, MK-0966; 4-(4 methylsulfonylpheny1)-3-pheny1-2- (5H)-furanone: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. Pbarmacol. Exp. Baer. (1999) 290:551–560.
  • FERREIRA SH: The role of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesics. Drugs (1993) 46 (Supp1.1) :1–9.
  • INOUE K, MOTONAGA A, T et al.: Mechanism of anti-inflammatory action of etodolac. Arzneimittelforscbung (1991) 41:235–239.
  • SENNA G.F, BETTELI C, GIVANNI S, SCARICABAROZZI I, ANDRI LG: Antihistaminic activity of nimesulide, a nonsteroidal anti-inflammatory drug. Allergy and Chia. Immunol. (1993) 9(2). (Abstract 241).
  • BERTI F, ROSSONI G, BUSCHI A, ROBUSCHI, M, VILLA LM: Antianaphylactic and antihistaminic activity of the non-steroidal anti-inflammatory compound nimesulide in guinea-pig. Arzneimittelforscbung / Drug Res. (1990) 40:1011–1016.
  • ROSSONI G, BERTI E BUSCHI A, VILLA LM, DELLA BELLA D: New data concerning the antianaphylactic and antihistaminic activity of nimesulide. Drugs (1993) 46\(Supp1.1):22–28.
  • TAVARES IA, BORRELLI E WELSH NJ: Inhibition of gastric acid secretion by nimesulide: a possible factor in its gastric tolerability. OM. Exp. Rheumatol. (2001) 19(1 Suppl. 22):513–515.
  • OTTONELLO L, DAPINO P, PASTORINO G, DALLEGRI F: Inhibition of the neutrophil oxidative response induced by the oral administration of nimesulide in normal volunteers. Lab. Immunol. (1992) 37:91–96.
  • •Nimesulide inhibits the production of neutrophil superoxide anions in human subjects.
  • CAPECCHI PL, CECCATELLI L, BEERMANN U, LAGHI PASINI F, DI PERRI F: Inhibition of neutrophil function in vitro by nimesulide. Preliminary evidence of an adenosine-mediated mechanism. Arzneimittelforscbung / Drug Res. (1993) 43:992–996.
  • FAHMI H, HEY, ZHANG M, MARTEL-PELLETIER J, PELLETIER JP, DI BATTISTA JA: Nimesulide reduces- lbeta-induced cyclooxygenase-2 gene expression in human synovial fibroblasts. Osteoartbritis Cartilage (2001) 9:332–340.
  • •Nimesulide inhibits the formation of COX-2 as well as its activity.
  • BENSEN WG, FIECHTNER JJ, JI et al.: Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo OM. Proc. (1999) 74:1095–1105.
  • CLEMETT D, GOA KL: Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs (2000) 59:957–980.
  • BACON PA: An overview of the efficacy of etodolac in arthritic disorders. Eur. Rheumatol. Lallamm. (1990) 10:22–34.
  • HUMBER LG: Etodolac (Lodine9, the first NSAID of the pyranocarboxylic acid class: a review of preclinical and clinical studies through 1992. Drugs of Today (1993) 29:265–293.
  • ••A good early review of etodolac.
  • LUCKER PW, PAWLOWSKI C, FRIEDRICH I, FAIELLA F, MAGNI E: Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. Eur. j Rheumatol. Infiamm. (1994) 14:29–38.
  • DEQUEKER J, HAWKEY C, KAHAN A et al.: Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: Results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br j Rheumatol. (1998) 37:946–951.
  • GOEI THE HS, LUND B, DISTEL MR, BLUHMKI E: A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoartbritis Cartilage (1997) 5:283–288.
  • HUSKISSON EC: Nimesulide, a balanceddrug for the treatment of osteoarthritis. OM. Exp. Rheumatol. (2001) 19(1 Suppl. 22):S21–S25.
  • SARZI-PUTTINI P, SANTANDREA S, BOCCASSINI L, PANNI B, CARUSO I: The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. OM. Exp. Rheumatol. (2001) 19(1 Suppl. 22):517–520.
  • CANNON GW, CALDWELL JR, HOLT P et al.: Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum. (2000) 43:978–987.
  • DAY R, MORRISON B, LUZA A etal.: Arandomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs. ibuprofen in patients with osteoarthritis. Arch. Intern. Med. (2000) 160:1781–1787.
  • MATHESON AJ, FIGGITT DP: Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs (2001) 61:833–865.
  • •A substantial review
  • PENA M: Etodolac: analgesic effects in musculoskeletal and postoperative pain. Rheumatol. Int. (1990) 10(Suppl.):9–16.
  • WOBER W: Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide. Rheumatology (1999) 38\(Supp1.1):33–38.
  • LECOMTE J, BUYSE H, TAYMANS J, MONTI T: Treatment of tendinitis and bursitis: a comparison of nimesulide and naproxen sodium in a double-blind parallel trial. Eur. j Rheumatol. Lallanam. (1994) 14:29–32.
  • POHJOLAINEN T, JEKUNEN A, AUTIO L, VUORELA H: Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine (2000) 25:1579–1585.
  • MALMSTROM K, DANIELS S, KOTEY P, SEIDENGERG BC, DESJARDINS PJ: Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. °inner. (1999) 21:1653–1663.
  • SCOTT R, ELLIS E, UPTON LG: Double-blind evaluation of etodolac (200 mg, 400 mg) compared with zomepirac (100 mg) and placebo on third molar extraction pain. Oral Surg. Oral Med. Oral PathoL (1986) 62:638–642.
  • GIGLIO JA, CAMPBELL RL: Comparisonof etodolac, zomepirac, and placebo for relief of pain after oral surgery. I Oral Maxillofac. Surg. (1986) 44:765-770. 1873
  • GASTON GW, MALLOW RD, FRANK JE: Comparison of etodolac, aspirin and placebo for pain after oral surgery. Pharmacotherapy (1986) 6:199–205.
  • RAGOT JP, MONTI T, MACCIOCCHI A: Controlled clinical investigation of acute analgesic activity of nimesulide in pain after oral surgery. Drugs (1993) 46\(Supp1.1):162–167.
  • PIERLEONI P, TONELLI P, SCARICABAROZZI I: A double-blind comparison of nimesulide and ketoprofen in dental surgery. Drugs (1993) 46\(Suppl. 1):168–170.
  • FERRARI PARABITA G, ZANETTI U, SCALVINI F, ROSSI D, SCARICABAROZZI I: A controlled clinical study of the efficacy and tolerability of nimesulide vs. naproxen in maxillo-facial surgery. Drugs (1993) 46\(Suppl. 1):171–173.
  • MORRISON BW, CHRISTENSEN S, YUAN W, BROWN J, AMLANI S, SEIDENBERG B: Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomised, controlled trial. Clin. Therap. (1999) 21:943–953.
  • EHRICH EW, DALLOB A, LEPELEIR IDet al.: Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin. Pharmacol. Ther. (1999) 653:36–47.
  • REUBEN SS, CONNELLY NR: Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Ariesth. Analg. (2000) 91:1221–1225.
  • CASEY R, ZADRA J, KHONSARI H: Acomparison of etodolac (Ultradol) with acetaminophen plus codeine (Tylenol #3) in controlling post-surgical pain in vasectomy patients. Curr. Med. Res. Opin. (1997) 13:555–563.
  • THOMPSON JP, SHARPE E KIANI S, OWEN-SMITH 0: Effect of meloxicam on postoperative pain after abdominal hysterectomy. Br. J. Anaesth. (2000) 84:151–154.
  • Nimesulide: a multifactorial therapeutic approach to the inflammatory process? A 7-year clinical experience. Bennett A, Berti F, Ferreira S H (Eds) Drugs (1993) 46\(Supp1.1):1–283.
  • ••An extensive coverage of many aspects ofnimesulide.
  • REICIN A, BROWN J, JOVE M et al: of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. Am. J. Orthop. (2001) 30:40–48.
  • HUANG JJ, TAGUCHI A, HSU H, ANDRIOLE GL, Jr, KURZ A: Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, double-blinded, placebo-controlled trial. _J.. (2001) 13:94–97.
  • PULKKINEN M: Is there a rationale for the use of nimesulide in the treatment of dysmenorrhoea? Drugs of Today (2001) 37 (Suppl. B):31–38.
  • MORRISON BW, DANIELS SE, KOTEY P, CANTU N, SEIDENBERG B: Rofecoxib, a specific cyclooxygenase-2 inhibitor in primary dysmenorrhea: a randomized controlled trial. Obstet. Cyriecol (1999) 94:504–508.
  • ENGELHARDT G, HOMMA D, SCHLEGEL K, UTZMANN R, SCHNITZLER C: Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Irillamm. Res. (1995) 44:423–433.
  • GOYAL PK, CHANDRA J, UNNIKRISHNAN G, KUMARI S, PASSAH SM: Double blind randomized comparative evaluation of nimesulide and paracetamol as antipyretics. Indian Pediam (1998) 35:519–522.
  • SALZBERG R, GIAMBONINI S, MAURIZIO M, ROULET D, ZAHN J, MONTI T: A double-blind comparison of nimesulide and mefenamic acid in the treatment of acute upper respiratory tract infections in children. Drugs (1993) 46\(Suppl. 1):208–211.
  • CUNIETTI E, MONTI M, VIGANO A et al.: Nimesulide in the treatment of hyperpyrexia in the aged. Double-blind comparison with paracetamol. Armeimittelforschung (1993) 43:160–162.
  • SCHWARTZ JI, CHAN CC, MUKHOPADHYAY S etal.: Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. CM]. Pharmacol Ther (1999) 65:653–660.
  • WINDE G, SCHMID KW, SCHLEGEL W, FISCHER R, OSSWALD H, BUNTE H: Complete reversion and prevention of rectal adenomas in colectomized patients familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment: advantages of a low-dose nonsteroidal anti-inflammatory drug drug regimen in reversing adenomas exceeding 33 months. Dis. Colon Rectum (1995) 38:S13–S30.
  • •An interesting prospect for cancer prevention and treatment.
  • STEINBACH G, LYNCH PM, PHILLIPS RK etal.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl. J. Med. (2000) 342:1946–1952.
  • •An interesting prospect for cancer prevention and treatment.
  • MCGEER PL, SCHULZER M, MCGEER: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology (1996) 47:425–432.
  • •An interesting prospect for the prevention and treatment of AD.
  • PASINETTI GM: Cyclooxygenase and inflammation in the clinical progression of Alzheimer's disease. In: Therapeutic Roles of Selective COX-2 Inhibitors. Vane JR, Botting RIVI (Eds), William Harvey Press, London (2001): 191–205.
  • ••A good review of COX-2 and other factorsin AD.
  • PASINETTI GM, AISEN PS:-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience (1998) 87:319–324.
  • PENSTON JG, WORMSLEY KG: Review article: asymptomatic duodenal ulcers - implications of heterogeneity. Aliment. Pharmacol Ther. (1990) 4:557–567.
  • Physician's desk reference, Medical Economics Company, Montvale, NJ (2000).
  • ••A superb account of drugs marketed in theUSA.
  • Martindale: The complete drug reference 32m edition. Parfitt K (Ed.) Pharmaceutical Press, London (1999).
  • ••An excellent source of information aboutdrugs.
  • SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al: Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284:1247–1255.
  • ••An excellent large scale study showing the GI safety of celecoxib.
  • GARCIA RODRIGUEZ LA: Nonsteroidal drugs, ulcers and risk: A collaborative meta-analysis. Semin. Arthritis. (1997) 26(6 Suppl. 0:16–20.. SIMON LS, WEAVER AL, GRAHAM DY et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA (1999) 282:1921–1928.
  • SIMON LS, LANZA FL, LIPSKY PE etal.: Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. (1998) 41:1591–1602.
  • RUSSELL RI, STURROCK RD, TAHA AS: Upper GI findings parallel minimal GI prostaglandin suppression. Endoscopic studies of patients treated with etodolac. Musculoskel Med (1991) 8(4, suppl):560–S65.
  • NEUSTADT DH: Double blind evaluation of the longterm effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. j Rheumatol. (1997) 24\(Suppl. 47):17–22.
  • ARNOLD JD, SALOM IL, BERGER AE et al.: Comparison of gastrointestinal microbleeding associated with the use of etodolac, ibuprofen, indomethacin, and naproxen in normal subjects. Curr. Ther. Res. (1985) 37:730–738.
  • LANZA F, RACK MF, LYNN M, WOLF J, SANDA M: An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. j Rheumatol (1987) 14:338–341.
  • BIANCHI PORRO G, CARUSO I, PETRILLO M, MONTRONE E ARDIZZONE S: A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients. J. Intern. Med. (1991) 229:5–8.
  • SCHATTENKIRCHNER M: An updated safety profile of etodolac in several thousand patients. Eur. Rheumatol Inllamm. (1990) 10:56–65.
  • ••Etodolac safety evaluation in thousands ofpatients.. HAWKEY C, KAHAN A, STEINBRUCK K et al.: Gastrointestinal tolerability of compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br. J. Rheumatol (1998) 37:937-945. A large scale safety study of meloxicam.
  • MARINI U, SPOTTI D, MAGNI E, MONTI T: Double-blind endoscopic study comparing the effect of nimesulide and placebo on gastric mucosa of dyspeptic subjects. Drug Invest. (1990) 2:162–166.
  • HUSKISSON EC, MACCIOCCHI A, RAHLF, VW et al.: Nimesulide versus diclofenac in the treatment of osteoarthritis of the hip or knee: an active controlled equivalence study. Curr. Therap. Res. (1999) 60:253–265.
  • PORTO A, REIS C, PERDIGOTO R, GONCALVES M, FREITAS P, MACCIOCCHI A: Gastroduodenal tolerability of nimesulide and diclofenac in patients with osteoarthritis. Cum: Ther. Res. (1998) 59:654–665.
  • GARCIA RODRIGUEZ LA, CATTARUZZI C, TRONCON MG, AGOSTINIS L: Risk of hospitalisation for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch. Intern. Med. (1998) 158:33–39.
  • RAINSFORD KD: Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. Rheumatology (1999) 38\(Supp1.1):4–10.
  • LAINE L, HARPERS, SIMON T et al: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology (1999) 117:776–783.
  • •More evidence of the upper GI safety of rofecoxib.
  • HAWKEY C, LAINE L, SIMON T et al: Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum. (2000) 43:370–377.
  • •More evidence of the upper GI safety of rofecoxib.
  • BOMBARDIER C, LAINE L, REICIN A et al: Comparison of upper gastrointestinal of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl. Med. (2000) 343:1520–1528.
  • •Upper GI safety of rofecoxib is better than with naproxen, but various other safety aspects are not as favourable.
  • LANGMAN MJ, JENSEN DM, WATSON DJ et al.: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA (1999) 282:1929–1933.
  • •Evidence challenging the GI safety of rofecoxib over 6 months compared with other NSAIDs.
  • In Focus. Rofecoxib (Vioxx). Curr. Problems Pharmacovigilarice (2000) 26:13.
  • •Yellow Card reports raising doubts about the overall safety of rofecoxib.
  • SIGTHORSSON G, TIBBLE J, HAYLLAR J et al.: Intestinal permeability and inflammation in patients on NSAIDs. Gut (1998) 43:506–511.
  • TIBBLE JA, SIGTHORSSON G, FOSTER R, BJARNASON I: Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scandj Castroeriterol. (2000) 35:802–807.
  • BJARNASON I. Forthcoming non-steroidal anti-inflammatory drugs: are they really devoid of side effects? Ital. Castroenterol Hepatol (1999) 31\(Suppl. 1):S27–S36.
  • BJARNASON I, THJODLEIFSSON B: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract. Rheumatology (1999) 38 (Supp1.1):24–32.
  • SIGTHORSSON G, JACOB M, WRIGGLES WORTH J et al: Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiologic steps in the pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in the rat. Scam/. (1998) 33:728–735.
  • HAWKEY CJ, JACKSON L, HARPER SE, SIMON TJ, MORTENSEN E, LINES CR: Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. Aliment. Pharmacol Ther. (2001) 15:1–9.
  • SIGTHORSSON G, CRANE R, SIMON T et al: COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo indomethacin. Gut (2000) 47:527–532.
  • BREYER MD, HARRIS RC: Cyclooxygenase 2 and the kidney. Curr. Opin. Nephrol. Hypertens. (2001) 10:89–98.
  • •COX-2-selective drugs can damage the kidneys.
  • WHELTON A, MAURATH CJ, VERBURG KM, GEIS GS: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am. I Ther. (2000) 7:159–175.
  • BRATER DC, HARRIS C, REDFERN JS, GERTZ BJ: Renal effects of cox-2-selective inhibitors. Am. J. Nephrol. (2001) 21:1–15.
  • PERAZELLA MA, ERAS J: Are selective COX-2 inhibitors nephrotoxic? Am. Kidney Dis. (2000) 35:937–940.
  • Celebrex (celecoxib capsules) Product Information. New York, NY: GD Searle & Co. (1998).
  • BRATER DC: Evaluation of etodolac in subjects with renal impairment. Eur. Rheumatol Intlamm. (1990) 10:44–55.
  • SHAND DG, EPSTEIN C, KINBERG-CALHOUN J et al.: The effect of etodolac administration on renal function in patients with arthritis. juin. Pharmacy]. (1986) 26:269–274.
  • FURST DE: Meloxicam: selective COX-2 inhibition in clinical practice. Semin. Arthritis Rheum. (1997) 26(6 Suppl. 1):21–27.
  • LEONE R, CONFORTI A, GHIOTTO E, MORETTI U, VALVO E, VELO GP: Nimesulide and renal impairment. Eur. Clin. Pharmacy]. (1999) 55:151–154.
  • SWAN SK, RUDY DW, LASSETER KC et al.: Effect of cyclooxygenase inhibition on renal function in elderly persons receivinga low-salt diet. A randomised controlled trial. Ann. Int. Med. (2000) 133:1–9.
  • Vi0XX (rofecoxib tablets and oral suspension) Product Information. West Point, PA: Merck & Co, Inc. (1999).
  • MADDREY WC, MAURATH CJ, VERBURG KM, GEIS GS: The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am. Ther (2000) 7:153–158.
  • DAVIES NM, MCLACHLAN AJ, DAY RO, WILLIAMS KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacolcinet. (2000) 38:225–242.
  • MABEE CL, MABEE SW, BAKER PB, RB, LEVINE EJ: Fulminant hepatic failure associated with etodolac use. Am. J. Castroenterol. (1995) 90:659–661.
  • RAINSFORD KD: An analysis from clinico-epidemiological data of the principal adverse events from the COX-2-selective NSAID, nimesulide, with particular reference to hepatic injury. Itillammopharmacology (1998) 6:203–221.
  • WEISS P, MOUALLEM M, BRUCK R et al.: Nimesulide-induced hepatitis and acute liver failure. Isr. Med. Assoc. J. (1999) 1:89–91.
  • HUSKISSON EC, GHOZLAN R, KURTHEN R, DEGNER FL, BLUHMKI E: A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br Rheumatol. (1996) 35\(Suppl. 1):29–34.
  • WHELTON A, FORT JG, PUMA JA, NORMANDIN D, BELLO AE, VERBURG KM: Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. j Ther. (2001) 8:85–95.
  • BENNETT A: The importance of COX-2 inhibition for aspirin-induced asthma. Thorax (2000) 55\(Suppl. 2):554–556.
  • KARAKAYA G, KALYONCU AF: Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics. Allergy]. Immunopathol. (2000) 28:319–321.
  • STEVENSON DD, SIMON RA: Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. I Allergy Gift]. Immune]. (2001) 108:47–51.
  • DAHLEN B, SZCZEKLIK A, MURRAY JJ: Celecoxib in patients with asthma and aspirin intolerance. N Engl. I Med. (2001) 344:142.
  • PAULSON SK, VAUGHN MB, JESSEN SM et al.: Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. I Pharmacy] Exp. Ther. (2001) 297:638–645.
  • BROCKS DR, JAMALI F: Etodolac clinical pharmacokinetics. Gun. Pharmacoldnet. (1994) 26:259–274.
  • TURCK D, BUSCH U, HEINZEL G, NARJES H: Clinical pharmacokinetics of meloxicam. Armeimittelforschung (1997) 47:253–258.
  • BUSCH U, HEINZEL C, NARGES H, NEHMIZ G: Interaction of meloxicam with cimetidine, Maalox, or aspirin. j Gift]. Pharmacy]. (1996) 36:79–84.
  • BERNAREGGI A: Clinical pharmacokinetics of nimesulide. Pharmacoldnet. (1998) 35:247–274.
  • LAPICQUE F, VERGNE P, JOUZEAU JY et al: Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. Clin. Pharmacoldnet. (2000) 39:369–382.
  • CHERIE-LIGNERE G, TOMBOLINI U, PANARACE G, ABBIATI G, MONTEGNANI G: La nimesulide nel liquido sinoviale di pazienti con artrite reumatoide. Farmaci e Terapia (1990) 7:173–176.
  • DEPRE M, EHRICH E, VAN HECKEN A et al: Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur. j Clin. Pharmacy] (2000) 56:167–174.
  • TANG C, SHOU M, MEI Q, RUSHMORE TH, RODRIGUES AD: Major role of human liver microsomal P450 2C9 in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. Pharmacy] Exp. Ther. (2000) 293:453–459.
  • CARINI M, ALDINI G, STEFANI R, MARINELLO C, FACINO RM: Mass spectrometric characterisation and HPLC determination of the main urinary metabolites of nimesulide in man. I Pharm. Blamed. Anal (1998) 18:201–211.
  • BREE F, NGUYEN P, URIEN S, ALBENGRES E, MACCIOCCHI A, TILLEMENT JP: Nimesulide binding to components within blood. Drugs (1993) 46\(Supp1.1)83–90.

Websites

  • http://biz.yahoo.comiprnews/000327/ pa_merck_v_l.html informs investigators of preliminary results of gastrointestinal outcomes study with Vi0XX R.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.